Quarterly report pursuant to Section 13 or 15(d)

Long-Term Debt and Other Financings - Novartis Note (Details)

v3.21.1
Long-Term Debt and Other Financings - Novartis Note (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Oct. 21, 2020
May 31, 2005
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Dec. 31, 2017
Dec. 31, 2015
Sep. 30, 2015
Long-term debt                
Debt amount     $ 18,855          
Revenue from contracts with customers     $ 19 $ 500        
Novartis Note                
Long-term debt                
Research and development expenses funded through loan facility, maximum (as a percent)   75.00%            
Maximum borrowing capacity under loan agreement   $ 50,000            
Interest rate at period end (as a percent)     2.26%          
Amount by which note will be reduced upon achievement of specified milestones               $ 7,300
Debt amount     $ 9,100   $ 9,100      
Reduction in debt obligation $ 7,300              
Novartis Note | Six-month LIBOR                
Long-term debt                
Basis spread on variable rate   2.00%            
Novartis International | License Agreement                
Long-term debt                
Revenue from contracts with customers 25,000   $ 0   $ 0 $ 10,000 $ 37,000  
Cash payment received $ 17,700           $ 37,000